-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, driven by a series of favorable policies, local pharmaceutical companies have increased their enthusiasm for innovation, increased investment in research and development, and the number of approved new drugs has also shown a continuous growth tre.
It is worth noting that as more and more pharmaceutical companies join the innovation track, the pace of internationalization of a large number of pharmaceutical companies has also begun to accelera.
Recently, it was reported that the international multi-center phase III clinical trial of 2 innovative drugs of Hengrui Medicine of camrelizumab for injection (Erica®) combined with apatinib mesylate tablets (Aitan®) (SHR-1210-III-310) The independent data monitoring committee (IDMC) judged that the primary endpoint of the study met the protocol-preset superiority standa.
It is understood that camrelizumab is a humanized PD-1 monoclonal antibody independently developed by Hengrui Medicine and has intellectual property righ.
Eight indications have been approved in the five major tumor types of cancer and lymphoma, and it is one of the domestic PD-1 products with a large number of approved indications and a wide range of tumor typ.
This time, camrelizumab was judged to meet the pre-set superiority standard of the main research endpoint, which is widely believed in the industry to promote the accelerated internationalization of Hengrui's innovative dru.
In fact, in recent years, Hengrui Medicine is vigorously promoting scientific and technological innovation and internationalization strate.
At present, it has established R&D centers in China, the United States, Europe, Australia, and Japan, forming a large-scale, specialized, A global R&D team with comprehensive capabilities, including a total of more than 170 overseas R&D teams, has fully launched the work mode of the global product development team to effectively improve the efficiency of global clinical tria.
In addition, according to incomplete statistics, Hengrui Medicine has carried out a total of nearly 20 international clinical trials, including 7 international multi-center Phase III projects, and more than 10 studies are in the preparatory sta.
In order to cope with the ever-increasing competition in the pharmaceutical market, the pressure of price reduction brought about by domestic centralized procurement, and the continuous squeeze on the return space of innovative drugs after they are launched, some powerful local innovative pharmaceutical companies have begun to accelerate their "going oversea.
In addition to Hengrui Medicine, BeiGene is also one of the companies with more international layouts and faster progre.
It is reported that on February 19 this year, BeiGene announced that its zanubrutinib has been approved by the Swiss Food and Drug Administration for the treatment of adults with Waldenström macroglobulinemia (WM) who have received at least one prior thera.
Or as a first-line treatment option for WM patients who are not suitable for chemoimmunothera.
The product has been approved for the first time in the world in the United States in November 2019, and has become a new domestic anti-cancer drug going overse.
It has subsequently been approved for marketing in China, Canada, Australia, Russia, the European Union and other countries and regio.
It is currently commercialized The footprint has covered 44 markets around the wor.
In addition, there are still more than 40 drug regulatory filings under review worldwi.
According to data, since Microchip authorized Chidamide to HUYA in the United States at a price of tens of millions of dollars in 2007, innovative pharmaceutical companies have continued to emer.
Pen, involving a large number of pharmaceutical companies such as Rongchang Bio, Renfu Pharmaceutical, and Livzon Gro.
The industry believes that in the future, in order to expand the market scope and better avoid the influence of medical insurance cost control, more and more domestic pharmaceutical companies will accelerate the promotion of products overseas and promote the international strategic layo.
However, it should be noted that there are still many uncertainties in the export of domestic dru.
If Chinese pharmaceutical companies want to accelerate the development of overseas markets, in addition to accelerating innovation, in terms of intellectual property distribution, overseas clinical execution capabilities, and overseas commercialization capabilities, e.
It also needs to be further strengthen.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
It is worth noting that as more and more pharmaceutical companies join the innovation track, the pace of internationalization of a large number of pharmaceutical companies has also begun to accelera.
Recently, it was reported that the international multi-center phase III clinical trial of 2 innovative drugs of Hengrui Medicine of camrelizumab for injection (Erica®) combined with apatinib mesylate tablets (Aitan®) (SHR-1210-III-310) The independent data monitoring committee (IDMC) judged that the primary endpoint of the study met the protocol-preset superiority standa.
It is understood that camrelizumab is a humanized PD-1 monoclonal antibody independently developed by Hengrui Medicine and has intellectual property righ.
Eight indications have been approved in the five major tumor types of cancer and lymphoma, and it is one of the domestic PD-1 products with a large number of approved indications and a wide range of tumor typ.
This time, camrelizumab was judged to meet the pre-set superiority standard of the main research endpoint, which is widely believed in the industry to promote the accelerated internationalization of Hengrui's innovative dru.
In fact, in recent years, Hengrui Medicine is vigorously promoting scientific and technological innovation and internationalization strate.
At present, it has established R&D centers in China, the United States, Europe, Australia, and Japan, forming a large-scale, specialized, A global R&D team with comprehensive capabilities, including a total of more than 170 overseas R&D teams, has fully launched the work mode of the global product development team to effectively improve the efficiency of global clinical tria.
In addition, according to incomplete statistics, Hengrui Medicine has carried out a total of nearly 20 international clinical trials, including 7 international multi-center Phase III projects, and more than 10 studies are in the preparatory sta.
In order to cope with the ever-increasing competition in the pharmaceutical market, the pressure of price reduction brought about by domestic centralized procurement, and the continuous squeeze on the return space of innovative drugs after they are launched, some powerful local innovative pharmaceutical companies have begun to accelerate their "going oversea.
In addition to Hengrui Medicine, BeiGene is also one of the companies with more international layouts and faster progre.
It is reported that on February 19 this year, BeiGene announced that its zanubrutinib has been approved by the Swiss Food and Drug Administration for the treatment of adults with Waldenström macroglobulinemia (WM) who have received at least one prior thera.
Or as a first-line treatment option for WM patients who are not suitable for chemoimmunothera.
The product has been approved for the first time in the world in the United States in November 2019, and has become a new domestic anti-cancer drug going overse.
It has subsequently been approved for marketing in China, Canada, Australia, Russia, the European Union and other countries and regio.
It is currently commercialized The footprint has covered 44 markets around the wor.
In addition, there are still more than 40 drug regulatory filings under review worldwi.
According to data, since Microchip authorized Chidamide to HUYA in the United States at a price of tens of millions of dollars in 2007, innovative pharmaceutical companies have continued to emer.
Pen, involving a large number of pharmaceutical companies such as Rongchang Bio, Renfu Pharmaceutical, and Livzon Gro.
The industry believes that in the future, in order to expand the market scope and better avoid the influence of medical insurance cost control, more and more domestic pharmaceutical companies will accelerate the promotion of products overseas and promote the international strategic layo.
However, it should be noted that there are still many uncertainties in the export of domestic dru.
If Chinese pharmaceutical companies want to accelerate the development of overseas markets, in addition to accelerating innovation, in terms of intellectual property distribution, overseas clinical execution capabilities, and overseas commercialization capabilities, e.
It also needs to be further strengthen.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
